Previous 10 | Next 10 |
A US House Committee on 30th September passed a bill that could legalize marijuana. The bill seeks to decriminalise and deschedule cannabis, putting it in the same category as nicotine. As a result, the cannabis industry could experience significant growth, thus boosting stock p...
Distillate Capital Partners was formed in 2017 and is based in Chicago, IL. The fund strategies use cash-flow-based measures of value and quality that are designed to avoid accounting distortions that we believe have rendered many traditional metrics less relevant in an increasingly asset...
Shares of Jazz Pharmaceuticals have been under pressure in the last few months on what appears to be investor concern about the durability of the company’s narcolepsy franchise. The threats are real - new narcolepsy drugs and primarily Xyrem going generic in 2023, and the high ...
Top Cannabis Stocks For Long Term Investing In 2021 Are you looking for ways to invest in top marijuana stocks in 2021? Right now, the cannabis sector has been trading near some of its lowest market value this year. In October inflation concerns continue to negatively impact the mar...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Other drug companies focused on treatments for narcoplepsy are down in trading today following Takeda's (TAK -9.3%) announcement that it is suspending phase 2 studies of narcolepsy treatment TAK-994. Avadel's (AVDL -4.0%) FT218 has an FDA PDUFA date of October 15. The candidate is a new formu...
Today, we revisit biopharma name Zogenix, Inc. for the first time since early this year. Its recently approved compound FINTEPLA continues to ramp up sales and some new approved indications may be on the horizon in the near future. A full investment analysis is presented in the pa...
Shares of the Ireland-based biopharmaceutical company Jazz Pharmaceuticals (JAZZ) have declined 26.7% over the past three months. While the company’s recent drug approvals and collaborations could boost its price, its mixed financials and uncertain growth potential are concerning. So, ...
September's been a rough month for the stock market, and on Monday, the S&P 500 had its worst day in months, falling 1.7%. Stocks across the board have been declining of late, and for investors, that has created some attractive buying opportunities along the way. While you might...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
Jazz Pharmaceuticals plc Website:
Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance PR Newswire – 15% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – O...
Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting PR Newswire Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN , July 25, 20...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals In celebration of Pride Month , we were joined by Celia Sandhya Daniels (she/they) who led an insightful discussion aimed at educating, raising awareness and calling for unders...